Tonix's depression fail; Lilly exercises option in Sitryx deal; Milner stops fight against Abcam acquisition
Tonix drops depression drug after PhII failure: Tonix Pharmaceuticals is discontinuing its major depressive disorder program, TNX …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.